SCHEMBL1157930

SCHEMBL1157930

FC(F)Oc1ccc(N(Cc2cccnc2)c2cccnc2)cc1OCC1CC1

nearest known ligand 0.52

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
PDE4D Q08499 18/20 0.52
PDE4B Q07343 8/20 0.52
PDE4A P27815 6/20 0.52
PDE4C Q08493 6/20 0.52
PDE5A O76074 1/20 0.50
ABCB11 O95342 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1157762 0.95 PDE4D (0.52) PDE4DPDE4BPDE4APDE4CPDE5A
SCHEMBL1157297 0.89 PDE4D (0.54) PDE4DPDE4BPDE4APDE4CPDE5A
SCHEMBL3120236 0.88 PDE4D (0.58) PDE4DPDE4BPDE4APDE4CPDE5A
SCHEMBL1157939 0.87 FGFR1 (0.43) PDE4DPDE4BPDE4APDE4C
SCHEMBL1157552 0.86 PDE4D (0.46) PDE4DPDE4BPDE4APDE4CPDE5A
SCHEMBL1157384 0.85 PDE4A (0.50) PDE4DPDE4BPDE4APDE4C
SCHEMBL1157650 0.85 PDE4D (0.51) PDE4DPDE4BPDE4APDE4CPDE5A
SCHEMBL1157901 0.85 PDE4D (0.46) PDE4DPDE4BPDE4APDE4CPDE5A
SCHEMBL3131819 0.84 PDE4D (0.53) PDE4DPDE4BPDE4APDE4CPDE5A
SCHEMBL1157700 0.82 PDE4B (0.44) PDE4DPDE4BPDE4APDE4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040230072-A1 Phosphodiesterase 4 inhibitors SCHUMACHER RICHARD A (US) 2004-11-18 US claimed
CN-1498211-A Aniline derivative using as phosphodiesterase 4 inhibitor ����˹��ҩ�﹫˾ 2004-05-19 CN claimed
EP-1353907-A2 PHOSPHODIESTERASE 4 INHIBITORS Memory Pharmaceutical Corporation (US) 2003-10-22 EP claimed
US-20030149052-A1 Phosphodiesterase 4 inhibitors MEMORY PHARMACEUTICALS CORP. 2003-08-07 US claimed
US-20020151566-A1 Phosphodiesterase 4 inhibitors MEMORY PHARMACEUTICALS CORP. (US) 2002-10-17 US claimed
WO-2002074726-A2 ANILINE DERIVATIVES USEFUL AS PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2002-09-26 WO claimed
US-20110046146-A9 Phosphodiesterase 4 inhibitors SCHUMACHER RICHARD A 2011-02-24 US disclosed
US-20090048255-A1 PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED ANILINE AND DIPHENYLAMINE ANALOGS SCHUMACHER RICHARD A 2009-02-19 US disclosed
US-7405230-B2 Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs MEMORY PHARMACEUTICALS CORPORATION (US) 2008-07-29 US disclosed
CN-100378075-C Aniline derivatives useful as phosphodiesterase 4 inhibitors MEMORY PHARMACEUTICALS INC (US) 2008-04-02 CN disclosed
US-7205320-B2 Phosphodiesterase 4 inhibitors MEMORY PHARMACEUTICALS CORP. (US) 2007-04-17 US disclosed
US-20070078139-A1 Phosphodiesterase 4 inhibitors SCHUMACHER RICHARD A 2007-04-05 US disclosed
CN-1688545-A phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs MEMORY PHARM CORP (US) 2005-10-26 CN disclosed
US-20040230072-A1 Phosphodiesterase 4 inhibitors SCHUMACHER RICHARD A (US) 2004-11-18 US disclosed
CN-1498211-A Aniline derivative using as phosphodiesterase 4 inhibitor ����˹��ҩ�﹫˾ 2004-05-19 CN disclosed
US-6699890-B2 N-SUBSTITUTED DIETHER ANILINE AND DIETHER DIPHENYLAMINE DERIVATIVES MEMORY PHARMACEUTICALS CORP. 2004-03-02 US disclosed
EP-1353907-A2 PHOSPHODIESTERASE 4 INHIBITORS Memory Pharmaceutical Corporation (US) 2003-10-22 EP disclosed
US-20030149052-A1 Phosphodiesterase 4 inhibitors MEMORY PHARMACEUTICALS CORP. 2003-08-07 US disclosed
US-20020151566-A1 Phosphodiesterase 4 inhibitors MEMORY PHARMACEUTICALS CORP. (US) 2002-10-17 US disclosed
WO-2002074726-A2 ANILINE DERIVATIVES USEFUL AS PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2002-09-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030149052-A1 Phosphodiesterase 4 inhibitors PDE4A, PDE4B, PDE3A PDE4D 9/4885PDE4B 2/4885PDE4A 1/4885
US-20020151566-A1 Phosphodiesterase 4 inhibitors PDE4A, PDE4B, PDE3A PDE4D 9/4885PDE4B 2/4885PDE4A 1/4885
US-20040230072-A1 Phosphodiesterase 4 inhibitors PDE4A, PDE4B, PDE3A PDE4D 9/4885PDE4B 2/4885PDE4A 1/4885
US-20110046146-A9 Phosphodiesterase 4 inhibitors PDE4A, PDE4B, PDE3B PDE4D 9/4885PDE4B 2/4885PDE4A 1/4885
US-20070078139-A1 Phosphodiesterase 4 inhibitors PDE4A, PDE4B, PDE3B PDE4D 9/4885PDE4B 2/4885PDE4A 1/4885
US-20090048255-A1 PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED ANILINE AND DIPHENYLAMINE ANALOGS PDE4A, PDE4B, PDE3A PDE4D 8/4885PDE4B 2/4885PDE4A 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.